Dose determination for molecularly targeted therapies: Much Ado About Nothing

Literature reviews and meta-analyses of phase 1 studies are particularly difficult to perform and rarely draw useful conclusions due to the small size of individual studies and the varied populations. With the low rate of success in oncology drug development, the focus should turn to improving the efficiency of phase 1 studies.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lsAimK
via IFTTT